MedTrace Logo

A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

NCT04132570 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2021-01-22

No results posted yet for this study

Summary

The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.

Conditions

  • Rhinitis

Interventions

DRUG

Budesonide

Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.

OTHER

Placebo

Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.

Sponsors & Collaborators

  • Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

    lead INDUSTRY

Principal Investigators

  • Luo Zhang · BEIJING TONGREN HOSPITAL, CMU

  • Chunguang Shan · THE SECOND HOSPITAL TO HEBEI MEDICAL UNIVERSITY

  • Weiwei Liu · Cangzhou Center Hospital

  • Guoji Zhang · BAODING FIRST CENTER HOSPITAL

  • Yaozhong Han · The No. 2 Hospital of Baoding

  • Yongjian Ma · THE NO.2 PEOPLE'S HOSPITAL OG WEIFANG

  • Guanggang Shi · Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2020-01-22
Completion
2020-01-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04132570 on ClinicalTrials.gov